72,234 articles
HS-10380
HS-10380 (Obuprazine, TRTL-107) is Hansoh Pharma's oral D2/D3 and 5-HT1A partial agonist, 5-HT2A antagonist antipsychotic for schizophrenia; Phase 2b showed PANSS gains versus placebo and aripiprazole, now in Phase 3.
HS-10535
HS-10535, also known as MK-4082, is an investigational oral small-molecule GLP-1 receptor agonist for obesity developed by China's Hansoh Pharma and globally licensed to Merck & Co. in December 2024.
HS-20094
HS-20094 (olatorepatide, 奥莱泊肽) is Hansoh Pharma's once-weekly dual biased GLP-1/GIP receptor agonist for diabetes and obesity, licensed to Regeneron outside Greater China; Phase 3 showed up to 19.3% weight loss at 48 weeks.
HS-20118 (AVR-001)
HS-20118 (AVR-001) is Hansoh Pharma's oral cyclic peptide interleukin-23 receptor antagonist for moderate-to-severe plaque psoriasis, licensed to Avere Therapeutics in 2026; Phase 1 data showed a 6-7 day half-life supporting once-weekly dosing and PASI 75 rates up to 75%.
HSC-2
HSC-2 (HSC2, CVCL_1287, JCRB0622) is a well-differentiated human oral squamous cell carcinoma cell line established in 1989 in Japan from a 69-year-old man, carrying PIK3CA His1047Arg and TP53 splice mutations, non-invasive, and used in drug-screening panels.
HSC-3
HSC-3 (HSC3, JCRB0623, CVCL_1288) is a human oral squamous carcinoma cell line established in 1989 from a 64-year-old Japanese man's tongue cancer, derived from a cervical lymph node metastasis, with high metastatic potential and wide use in OSCC research.
HSC-4
HSC-4 (HSC4, CVCL_1289, JCRB0624) is a human tongue squamous cell carcinoma cell line established in 1989 from a 64-year-old Japanese man's cervical lymph node metastasis, used in over 150 OSCC studies.
HSD10 disease
HSD10 disease, also called HSD10 mitochondrial disease, is a rare X-linked neurometabolic disorder caused by HSD17B10 gene variants, fatal in most affected boys by early childhood.
HSD11B1
HSD11B1 (11β-HSD1, SDR26C1) is a human gene at 1q32.2 encoding a microsomal, NADP(H)-dependent enzyme that interconverts cortisol and cortisone, acting mainly as a cortisone reductase; mutations cause cortisone reductase deficiency and it is a drug target in metabolic and immune disease.
HSD11B2
HSD11B2 (hydroxysteroid 11-beta dehydrogenase 2, 11β-HSD2) is a human gene on 16q22.1 encoding an NAD-dependent enzyme that inactivates cortisol to cortisone, protecting the mineralocorticoid receptor and the fetus; defects cause apparent mineralocorticoid excess.
HSD17B1
HSD17B1 (hydroxysteroid 17-beta dehydrogenase 1, also EDH17B2, SDR28C1) is a human gene at 17q21.2 encoding 17β-HSD1, a 34.5-kDa homodimeric SDR enzyme that reduces estrone to estradiol using NADPH, inactivates androgens, and is a drug target in breast cancer and endometriosis.
HSF1
HSF1 (heat shock factor 1), master transcriptional regulator of the heat shock response, induces HSP chaperone genes via stress-triggered trimerization and HSE binding; elevated in cancer, degraded in Huntington disease.
HSG
HSG (Human Salivary Gland, CVCL_2517) is a human cancer cell line established in 1981 from an irradiated submandibular salivary gland but shown by STR profiling to be a HeLa derivative; ICLAC-00313, distinct from the HGS1-4 ovarian series.
HSK31858 (DPP1 inhibitor)
HSK31858, renamed florensocatib, is an oral non-covalent DPP1 (cathepsin C) inhibitor from Haisco, licensed to Chiesi outside greater China; SAVE-BE cut bronchiectasis exacerbations by 48-59%.
HSK39004
HSK39004 (AN01) is Haisco Pharmaceutical's inhaled dual PDE3/4 inhibitor for COPD maintenance, in dry powder and suspension forms, in Phase 3 in China and licensed to AirNexis for up to $1.063 billion.
HSK51155
HSK51155 is an oral, non-opioid analgesic candidate developed by China's Haisco Pharmaceutical, a selective Nav1.8 sodium channel inhibitor in phase 1 trials for migraine and licensed to AbbVie in 2026.
HSK55718
HSK55718 (HSK-55718) is Haisco Pharmaceutical's intravenous, small-molecule non-opioid NaV1.8 inhibitor analgesic for moderate-to-severe acute pain, in Phase II trials in China, with ex-Greater China rights licensed to AbbVie in April 2026.
HSK60002
HSK60002 is Haisco Pharmaceutical's class 1 oral small-molecule tablet, reported as a STAT6 PROTAC for inflammatory diseases. IND accepted July 2026, clinical approval August 2026 (atopic dermatitis, asthma), licensed to Sentivera for over $1.5 billion.
Hsp100/Clp protein family
The Hsp100/Clp family is a group of ring-shaped AAA+ ATPase chaperones, including ClpA, ClpB, and Hsp104, that use ATP to unfold proteins or dissolve aggregates.
Hsp104
Hsp104 (heat shock protein 104), yeast AAA+ hexameric disaggregase homologous to bacterial ClpB, dissolves protein aggregates, prions, and amyloids with Hsp70; lost in metazoans, studied for neurodegenerative disease therapy.
Hsp110 and related nucleotide-exchange factor families
The Hsp110/Grp170, HspBP1/Sil1, and BAG families are eukaryotic co-chaperone families that restart the Hsp70 cycle by driving ADP release, unlike bacteria, which have only GrpE.
Hsp70
Hsp70 (70 kDa heat shock protein, DnaK in bacteria) is a conserved ATP-driven molecular chaperone family that folds, translocates, and disaggregates proteins; discovered by Ritossa in Drosophila in 1962, with 13 human members including Hsp72, BiP, and mortalin.
Hsp90
Hsp90 is a family of about 90-kDa molecular chaperones that use ATP-driven conformational cycles to mature client proteins, including kinases, transcription factors, and E3 ubiquitin ligases.
Hsp90 buffering of genetic variation
Hsp90 buffering of genetic variation is the ability of the Hsp90 chaperone to hide the effects of genetic variants until stress or inhibition reveals them, making Hsp90 a capacitor of variation.
HSP90AA1
HSP90AA1 (Hsp86, HspC1) is the human chromosome 14q32.31 gene encoding Hsp90α, the stress-inducible cytosolic Hsp90 chaperone isoform, a homodimeric ATPase distinct from the essential constitutive paralog HSP90AB1.
HSP90AB1
HSP90AB1 (HSP 90-beta, Hsp90β, HSP84) is the human chromosome 6p21.1 gene encoding the constitutive cytosolic 90 kDa heat shock protein chaperone, an ATPase that matures client kinases and hormone receptors, distinct from stress-inducible HSP90AA1.
HSP90B1
HSP90B1 (GRP94, gp96, endoplasmin) is the human gene at 12q23.3 encoding the ER-resident HSP90-family chaperone that folds Toll-like receptors, integrins, and IGF clients; its regulated glycosylation links to osteogenesis imperfecta and cancer prognosis.
HSPA1A
HSPA1A (HSP70-1, HSP72) is a human intronless gene at 6p21.33 in the MHC class III region encoding the major stress-inducible 70 kDa Hsp70 chaperone, regulated by HSF-1, NF-Y, NF-kB, and CREB.
HSPA1B
HSPA1B (HSP70-2), human intronless gene at 6p21.33 in the MHC class III region, encodes a 70 kDa stress-inducible Hsp70 chaperone nearly identical to HSPA1A, HSF1-regulated, with eQTL rs400547 and male-fertility roles in mouse knockout.
HSPA6
HSPA6 (HSP70B′), heat shock protein family A member 6, Gene ID 3310 at 1q23.3: a strictly stress-inducible human Hsp70 chaperone, 643 aa, binding only Class B JDPs, implicated in cancer prognosis and drug resistance.